TY - JOUR
T1 - Gadolinium metallofullerenol nanoparticles inhibit cancer metastasis through matrix metalloproteinase inhibition
T2 - Imprisoning instead of poisoning cancer cells
AU - Meng, Huan
AU - Xing, Gengmei
AU - Blanco, Elvin
AU - Song, Yan
AU - Zhao, Lina
AU - Sun, Baoyun
AU - Li, Xiaoda
AU - Wang, Paul C.
AU - Korotcov, Alexandru
AU - Li, Wei
AU - Liang, Xing Jie
AU - Chen, Chunying
AU - Yuan, Hui
AU - Zhao, Feng
AU - Chen, Zhen
AU - Sun, Tong
AU - Chai, Zhifang
AU - Ferrari, Mauro
AU - Zhao, Yuliang
N1 - Funding Information:
The authors thank for the support of MOST 973 program (2009CB930204, 2011CB933403, 2010CB934000, 2012CB934000) and CAS Knowledge Innovation Program. This study was partly funded by National Natural Science Foundation of China (10875136), and U.S NIH/RCMI/NCRR (2G12RR003048) and DOD (W81XWH-10-1-0767). M.F., T.S., E.B., are grateful for the support of the U.S. DoD Innovator Award (W81XWH-09-1-0212), NIH U54CA143837 and U54CA151668, and the Ernest Cockrell Jr. Distinguished Endowed Chair.
PY - 2012/2
Y1 - 2012/2
N2 - The purpose of this work is to study the antimetastasis activity of gadolinium metallofullerenol nanoparticles (f-NPs) in malignant and invasive human breast cancer models. We demonstrated that f-NPs inhibited the production of matrix metalloproteinase (MMP) enzymes and further interfered with the invasiveness of cancer cells in tissue culture condition. In the tissue invasion animal model, the invasive primary tumor treated with f-NPs showed significantly less metastasis to the ectopic site along with the decreased MMP expression. In the same animal model, we observed the formation of a fibrous cage that may serve as a physical barrier capable of cancer tissue encapsulation that cuts the communication between cancer- and tumor-associated macrophages, which produce MMP enzymes. In another animal model, the blood transfer model, f-NPs potently suppressed the establishment of tumor foci in lung. Based on these data, we conclude that f-NPs have antimetastasis effects and speculate that utilization of f-NPs may provide a new strategy for the treatment of tumor metastasis. From the Clinical Editor: In this study utilizing metallofullerenol nanoparticles, the authors demonstrate antimetastasis effects and speculate that utilization of these nanoparticles may provide a new strategy in metastatic tumor therapy.
AB - The purpose of this work is to study the antimetastasis activity of gadolinium metallofullerenol nanoparticles (f-NPs) in malignant and invasive human breast cancer models. We demonstrated that f-NPs inhibited the production of matrix metalloproteinase (MMP) enzymes and further interfered with the invasiveness of cancer cells in tissue culture condition. In the tissue invasion animal model, the invasive primary tumor treated with f-NPs showed significantly less metastasis to the ectopic site along with the decreased MMP expression. In the same animal model, we observed the formation of a fibrous cage that may serve as a physical barrier capable of cancer tissue encapsulation that cuts the communication between cancer- and tumor-associated macrophages, which produce MMP enzymes. In another animal model, the blood transfer model, f-NPs potently suppressed the establishment of tumor foci in lung. Based on these data, we conclude that f-NPs have antimetastasis effects and speculate that utilization of f-NPs may provide a new strategy for the treatment of tumor metastasis. From the Clinical Editor: In this study utilizing metallofullerenol nanoparticles, the authors demonstrate antimetastasis effects and speculate that utilization of these nanoparticles may provide a new strategy in metastatic tumor therapy.
KW - Cancer metastasis
KW - Fibrous cage
KW - Matrix metalloproteinase
KW - Metallofullerenol nanoparticles
KW - Nanomedicine
UR - http://www.scopus.com/inward/record.url?scp=84855836038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855836038&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2011.08.019
DO - 10.1016/j.nano.2011.08.019
M3 - Article
C2 - 21930111
AN - SCOPUS:84855836038
SN - 1549-9634
VL - 8
SP - 136
EP - 146
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 2
ER -